![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, December 25, 2021 1:19:44 PM
And I would say that applies to developing an alternate revenue stream, also, through Clinigen.
Something has led to Humanigen becoming more resilient, and less fragile. I doubt that is because the company is going to accept a tender offering.
I'm really confident that the company has transitioned to becoming a revenue-funded entity.
And still, I have not seen a competitive product come onto the market designed to treat hospitalized and hypoxic patients, and certainly not one that even approaches lenzilumab's efficacy.
To date, there have been almost 9B vaccinations, 1B just in the last month. There's been no relief on hospitals and medical staff.
Lenz will provide that relief. Our market prospects look better to me now than they ever have.
Merry Christmas to you, as well, 10nisman.
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM